304 related articles for article (PubMed ID: 29356953)
1. The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.
Dueckelmann AM; Fink D; Harter P; Heinzelmann V; Marth C; Mueller M; Reinthaller A; Tamussino K; Wimberger P; Sehouli J
Arch Gynecol Obstet; 2018 Apr; 297(4):837-846. PubMed ID: 29356953
[TBL] [Abstract][Full Text] [Related]
2. Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience.
Tempfer CB; Celik I; Solass W; Buerkle B; Pabst UG; Zieren J; Strumberg D; Reymond MA
Gynecol Oncol; 2014 Feb; 132(2):307-11. PubMed ID: 24275155
[TBL] [Abstract][Full Text] [Related]
3. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC).
Odendahl K; Solass W; Demtröder C; Giger-Pabst U; Zieren J; Tempfer C; Reymond MA
Eur J Surg Oncol; 2015 Oct; 41(10):1379-85. PubMed ID: 26138283
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A;
Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910
[TBL] [Abstract][Full Text] [Related]
5. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis.
Nadiradze G; Giger-Pabst U; Zieren J; Strumberg D; Solass W; Reymond MA
J Gastrointest Surg; 2016 Feb; 20(2):367-73. PubMed ID: 26511950
[TBL] [Abstract][Full Text] [Related]
6. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy.
Solass W; Kerb R; Mürdter T; Giger-Pabst U; Strumberg D; Tempfer C; Zieren J; Schwab M; Reymond MA
Ann Surg Oncol; 2014 Feb; 21(2):553-9. PubMed ID: 24006094
[TBL] [Abstract][Full Text] [Related]
8. Low-dose pressurized intraperitoneal aerosol chemotherapy (PIPAC) as an alternative therapy for ovarian cancer in an octogenarian patient.
Giger-Pabst U; Solass W; Buerkle B; Reymond MA; Tempfer CB
Anticancer Res; 2015 Apr; 35(4):2309-14. PubMed ID: 25862894
[TBL] [Abstract][Full Text] [Related]
9. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
Wimberger P; Wehling M; Lehmann N; Kimmig R; Schmalfeldt B; Burges A; Harter P; Pfisterer J; du Bois A
Ann Surg Oncol; 2010 Jun; 17(6):1642-8. PubMed ID: 20165986
[TBL] [Abstract][Full Text] [Related]
10. Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC).
Blanco A; Giger-Pabst U; Solass W; Zieren J; Reymond MA
Ann Surg Oncol; 2013 Jul; 20(7):2311-6. PubMed ID: 23377563
[TBL] [Abstract][Full Text] [Related]
11. Oncological Outcomes After Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in the Treatment of Peritoneal Carcinomatosis.
Tidadini F; Abba J; Quesada JL; Trilling B; Bonne A; Foote A; Faucheron JL; Arvieux C
J Gastrointest Cancer; 2023 Jun; 54(2):632-641. PubMed ID: 35778645
[TBL] [Abstract][Full Text] [Related]
12. Pressurized Intraperitoneal Aerosol Chemotherapy with Cisplatin and Doxorubicin in Women with Peritoneal Carcinomatosis: A Cohort Study.
Tempfer CB; Rezniczek GA; Ende P; Solass W; Reymond MA
Anticancer Res; 2015 Dec; 35(12):6723-9. PubMed ID: 26637888
[TBL] [Abstract][Full Text] [Related]
13. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
[TBL] [Abstract][Full Text] [Related]
14. Pressurized intraperitoneal aerosol chemotherapy as an innovative approach to treat peritoneal carcinomatosis.
Tempfer CB
Med Hypotheses; 2015 Oct; 85(4):480-4. PubMed ID: 26277656
[TBL] [Abstract][Full Text] [Related]
15. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study.
Tempfer CB; Winnekendonk G; Solass W; Horvat R; Giger-Pabst U; Zieren J; Rezniczek GA; Reymond MA
Gynecol Oncol; 2015 May; 137(2):223-8. PubMed ID: 25701703
[TBL] [Abstract][Full Text] [Related]
16. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Procedure for Non-resectable Peritoneal Carcinomatosis (with Video).
Cazauran JB; Alyami M; Lasseur A; Gybels I; Glehen O; Bakrin N
J Gastrointest Surg; 2018 Feb; 22(2):374-375. PubMed ID: 28900843
[TBL] [Abstract][Full Text] [Related]
17. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
[TBL] [Abstract][Full Text] [Related]
18. Nutritional status, cachexia, and anorexia in women with peritoneal metastasis and intraperitoneal chemotherapy: a longitudinal analysis.
Hilal Z; Rezniczek GA; Klenke R; Dogan A; Tempfer CB
J Gynecol Oncol; 2017 Nov; 28(6):e80. PubMed ID: 29027398
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
Duska LR; Java JJ; Cohn DE; Burger RA
Gynecol Oncol; 2015 Nov; 139(2):221-7. PubMed ID: 26335594
[TBL] [Abstract][Full Text] [Related]
20. Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients.
Tangjitgamol S; See HT; Manusirivithaya S; Levenback CF; Gershenson DM; Kavanagh JJ
Int J Gynecol Cancer; 2004; 14(5):804-14. PubMed ID: 15361188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
